Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moolec ScienceMLEC -12.43%44 3-1 Month Momentum % is 14.09% as of Jul. 22, 2026. GuruFocus rates MLEC with a GF Score™ of 44/100 and a GF Value™ of $84.84 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,388 Biotechnology companies, Moolec Science ranks better than 86.46% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-22), Moolec Science's 3-1 Month Momentum % is 14.09%.
The industry rank for Moolec Science's 3-1 Month Momentum % or its related term are showing as below:
MLEC's 3-1 Month Momentum % is ranked better than 86.46% of 1388
companies
in the Biotechnology industry
Industry Median: -12.625
vs MLEC: 14.09
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Moolec Science 3-1 Month Momentum % Related Terms
MLEC vs GNPX, ADIL, APVO: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Moolec Science's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Moolec Science's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moolec Science (MLEC) has a 3-1 Month Momentum % of 14.09% as of Jul. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #188 out of 1388 companies in the Biotechnology industry, placing it in the top 13.5%.
Is Moolec Science's 3-1 Month Momentum % too high?
Moolec Science's current 3-1 Month Momentum % is 14.09%. Based on the distribution chart, Moolec Science ranks #188 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Moolec Science has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's 3-1 Month Momentum % compare to GNPX and ADIL?
According to the Biotechnology industry distribution chart, Moolec Science ranks #188 out of 1388 companies for 3-1 Month Momentum %. This places Moolec Science in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Moolec Science and its competitors. Moolec Science's current 3-1 Month Momentum % is 14.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.40 — trading 91.3% below its estimated fair value. The current 3-1 Month Momentum % is 14.09%. Moolec Science's overall GF Score™ is 44/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Moolec Science (MLEC), the current 3-1 Month Momentum % is 14.09% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.40 is trading 91.3% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
3-1 Month Momentum %: 14.09%
GF Value™: $84.84 vs. price of $7.40 (91.3% below fair value)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
44GF Score
Get the complete analysis for MLEC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
